ResMed Inc. (RMD)

Over the past six months, ResMed's stock has increased by 10.71%. In mid-2023, concerns about GLP-1 weight loss drugs impacted the stock, but demand for ResMed's devices has remained robust. On July 31, 2025, ResMed announced its fourth-quarter fiscal year 2025 financial results, surpassing EPS expectations but falling short on revenue. In August 2025, Nicole Mowad-Nassar was elected to ResMed's board, and Rich Sulpizio announced his retirement. In October 2025, ResMed's CEO, Michael Farrell, sold $2.26 million in shares. Analyst ratings have generally been positive.

ResMed's products address long-term conditions, creating a stable demand that is generally less affected by economic changes. The market for its products has a seasonal cadence, but the underlying need for continuous therapy for chronic conditions suggests a relatively consistent demand throughout the year.

ResMed, Inc. is a global medical equipment company specializing in cloud-connected devices for respiratory conditions like sleep-disordered breathing and COPD. The company, originally founded in Australia but now based in San Diego, operates in the healthcare sector, focusing on medical devices and digital health. Its business is divided into Sleep and Respiratory Care, and Software as a Service (SaaS). Major products include CPAP machines, masks, humidifiers, and ventilators. The SaaS unit provides business management software for out-of-hospital care providers. ResMed uses its hardware and SaaS data to generate insights, improve patient outcomes, and reduce healthcare costs.

ResMed is a global company operating in over 140 countries with more than 10,000 employees. Approximately two-thirds of its revenue is generated in the Americas, with the remaining balance coming from Europe, Japan, and Australia.

ResMed maintains a strong brand reputation as a global leader in medical technology, particularly in sleep and respiratory care. The company is recognized for its innovative solutions and its competitive position is considered near-unassailable. In March 2025, ResMed unveiled a brand evolution strategy to unify its brands under a single health technology identity. Recent efforts to enhance its digital offerings include the acquisition of Medifox Dan in 2022 and Somnoware in 2023, as well as the launch of new patient-centric digital products.

ResMed Inc. is primarily owned by institutional shareholders, who collectively hold 62.75% of the company's stock. Insiders own 4.25%, and retail investors hold 33.00%. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. The largest individual shareholder is Christopher G. Roberts, who owns 1.16% of the company.